Solid Biosciences (SLDB) Earnings Date & Reports

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

SLDB is expected to report earnings to fall 12.88% to -45 cents per share on August 17

Solid Biosciences SLDB Stock Earnings Reports

Q2'26

Est.

$-0.45

Q1'26

Beat

by $0.13

Q4'25

Beat

by $0.09

Q3'25

Beat

by $0.17

Q2'25

Beat

by $0.22

The last earnings report on May 12 showed earnings per share of -51 cents, beating the estimate of -64 cents. With 278.12K shares outstanding, the current market capitalization sits at 817.13M.

View a ticker or compare two or three

Compare

SLDB

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for SLDB